A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study (Q36528653)

14 August 2017

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study (English)

1 reference

14 August 2017

phase II clinical trial

0 references

California

0 references

metastatic breast cancer

1 reference

12

David R Gandara

1 reference

14 August 2017

Thehang H Luu

1

1 reference

14 August 2017

Robert J Morgan

2

1 reference

14 August 2017

Lucille Leong

3

1 reference

14 August 2017

Dean Lim

4

1 reference

14 August 2017

Mark McNamara

5

1 reference

14 August 2017

Jana Portnow

6

1 reference

14 August 2017

Paul Frankel

7

1 reference

14 August 2017

David D Smith

8

1 reference

14 August 2017

James H Doroshow

9

1 reference

14 August 2017

Carol Wong

10

1 reference

14 August 2017

Ana Aparicio

11

1 reference

14 August 2017

George Somlo

13

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

14 August 2017

Clinical Cancer Research

1 reference

14 August 2017

14

1 reference

14 August 2017

21

1 reference

14 August 2017

7138-7142

1 reference

We should desist using RECIST, at least in GIST.

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Histone deacetylase inhibitors: biology and mechanism of action

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Discovery and development of SAHA as an anticancer agent

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Worms gang up on bacteria

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Gene expression profiling predicts clinical outcome of breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Significance analysis of microarrays applied to the ionizing radiation response

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Expression of hemidesmosomes and component proteins is lost by invasive breast cancer cells.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3543872

A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18981013

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The fundamental role of epigenetic events in cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18981013

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-08-0122

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

18981013

1 reference